STUDY DESIGN AND METHODS: RBC antigen
genotyping was performed on chronically transfused pediatric SCA patients, using PreciseType human erythrocyte antigen (HEA), RHCE, and RHD BeadChip arrays. All patients received C/c, E/e, and K serologically matched units (Category 1); patients with prior RBC antibodies were also matched for 
CONCLUSIONS: Alloimmunization incidence was
higher in those with prior RBC antibodies, suggesting that past immunologic responders are at higher risk for future alloimmunization and therefore may benefit from more extensive antigen matching beyond C/c, E/e, K, SCA, with a prevalence of up to 45%. [1] [2] [3] [4] Although limited matching of C/c, E/e, and K antigens for all SCA patients has reduced this rate from 27% to 75% without limited matching to 5% to 14% with limited matching, 1, 2, [5] [6] [7] [8] [9] [10] [11] alloimmunization remains a prevalent and clinically significant problem in SCA. 12, 13 Alloimmunization may lead to challenges in identifying appropriate antigen-negative blood for patients. Undetected alloantibodies present a risk for patients to receive antigen-positive blood with resultant hemolytic transfusion reactions. 14, 15 Finally, patients with a history of one or more alloantibodies are at increased risk of forming new RBC antibodies with subsequent transfusion exposures. 16 Extended RBC antigen typing of SCA patients is necessary to provide antigen-matched RBC transfusions and to guide the identification of new RBC antibodies. RBC antigen genotyping allows for DNA-based prediction of minor RBC antigen expression based on single-nucleotide polymorphisms (SNPs). 17 Additionally, Rh antigen variants are common in sickle cell disease (SCD) and individuals of African descent. 4 , and V/VS) and the ability to accurately type antigens in patients with recent RBC transfusions or patients with RBC allo-or autoantibodies that may interfere with serologic phenotype matching. 18 While the incidence of alloantibody formation has been reported in SCA, 19 there are little data regarding the frequency of RBC minor antigen mismatches in transfusion therapy for SCA, nor the frequency of exposure to mismatched antigens before new RBC alloantibody formation. The main purpose of this study was to determine the frequency of RBC minor antigen mismatches that occur during CTT for SCA patients following standard protocols for limited serologic antigen matching. Additionally, we sought to identify both the incidence of new alloantibody formation and the frequency of antigen exposures before the antibody formation, during CTT.
MATERIALS AND METHODS
A prospective observational study of children ages 3 to 20 years with SCA (HbSS or HbSb 0 thalassemia genotypes)
on CTT for at least the past 6 months was conducted at Children's Healthcare of Atlanta (CHOA), which has three hospital-based pediatric hematology infusion centers and blood banks, and at Children's National Medical Center (CNMC), which has one infusion center and blood bank. All new antibodies identified during the study period were recorded, and previous transfusions during the study period were reviewed to determine the number and frequency of antigen exposures (as determined by human erythrocyte antigen [HEA]-LR) before the antibody detection. The incidence of alloantibody formation was calculated for patients on Category 1-matched transfusions and Category 2 transfusions.
RBC genotyping (HEA) methods
RBC minor antigen genotyping of the patients was performed using PreciseType HEA Molecular BeadChip assay (Immucor) to identify SNPs associated with 35 antigens in 11 blood group systems (Rh, Kell, Kidd, Duffy, MNS, Dombrock, Lutheran, Landsteiner-Wiener, Diego, Colton, and Scianna) and the RHCE and RHD BeadChip assays to detect more than 35 RHCE variants and more than 80 RHD variants (Immucor). For each assay, genomic DNA was extracted from whole blood per manufacturer instructions as previously described, for polymerase chain reaction (PCR)-based detection of individual polymorphisms. [21] [22] [23] For donor unit genotyping, genomic DNA was extracted from two to four segments of LR RBC units by using an automated DNA extractor and the blood DNA rWBC kit (InviGenius and InviMag, respectively, Stratec Molecular GmbH). All extracted genomic DNA samples were subjected to PCR amplification and analyzed using the prototype HEA-LR BeadChip assay (Immucor), which detects the same profile of RBC antigens as the PreciseType HEA assay, as previously reported. 24 RH variant testing of LR units was not performed since this testing required a larger quantity of DNA than could be extracted from LR unit segments; therefore, units were assumed to express conventional RH haplotypes. However, since both the PreciseType and the HEA-LR assays are able to detect the 733C>G (RhCE-L245V) and 1006G>T (RhCE-G336C) SNPs, the frequency of partial e genotypes based on these SNPs was determined for the donor units. HEA-LR genotype results were compared to available serologic phenotype records for each unit, and in cases of discrepancies, the HEA-LR assay was repeated in duplicate to verify or amend results. In cases where unit genotypes were known from previous donor testing by the blood donor center(s) using the HEA assay, the units were not tested by HEA-LR BeadChip.
HEA and RH antigen mismatch definitions
Each donor unit genotype was compared to the recipient's genotype to identify antigen mismatches. An antigen mismatch was defined as a recipient exposure to a RBC minor antigen that the recipient does not express. In cases where the HEA-LR result for an antigen was an indeterminate call (IC) or had low signal (LS) intensity, there was assumed to be no mismatch between donor unit and recipient. For recipients with the FY gene promoter region mutation that prevents erythroid-specific GATA-1 transcription factor binding and erythroid Fy b antigen expression, exposure to Fy b 1 units was not considered to be a mismatch, since these recipients are not at risk for antiFy b alloimmunization. 25 For U-(S-s-) patients, exposure to a S1 and/or s1 unit was considered to result in mismatch at the S and/or s antigen (one or two mismatches) and at the U antigen (additional mismatch). RH genotypes were categorized as either conventional (homozygous for conventional alleles or heterozygous for one variant and one conventional allele) or variant (homozygous or compound heterozygous for variant alleles, with no conventional allele detected). All units transfused were assumed to have conventional Rh antigen expression unless denoted as homozygous for ce(733G) with/without 1006T. Therefore, for patients with partial e, C, c, or D expression, all antigen-positive units transfused were assumed to be mismatched at the variant antigen, unless specific variant matching had been indicated (e.g., C-, e-, hr B -, D-). In patients with two or more SNPs identified in which the BeadChip assay could not distinguish cis versus trans position of each SNP (e.g., ce48C, 733G), the patient was categorized as not having a variant genotype that could result in an antigen mismatch.
Statistical analysis
Patients' clinical data and RBC genotyping results were stored in a Research Electronic Data Capture (REDcap) database, and statistical analyses were performed with computer software (SAS, Version 9.4, SAS Institute). Comparisons of continuous variables (age and CTT duration) between patients receiving Category 1-versus Category 2-matched transfusions were made by t test or by Wilcoxon rank-sum test for nonnormally distributed variables, with the normality of distribution assessed by the Shapiro-Wilk test. The categorical variable (sex) was compared by chisquare test. The frequencies of each RBC antigen in SCA patients versus in the donor RBC units were compared by chi-square or Fisher's exact test, as appropriate for sample size. Likewise, the frequencies of antigen mismatches among Category 1-versus Category 2-matched transfusions were compared by chi-square or Fisher's exact test, using the Bonferroni method to account for multiple comparisons. The incidence of new alloantibody detection was calculated as the number of new antibodies detected per number of units transfused during the study period, and incidence rates for Category 1 versus Category 2 transfusions. These Poisson incidence rates were compared to a ratio of 1 to test equality. For new alloantibodies detected during the study (e.g., anti-Js a ), the rates of exposure to the antigen in Category 1 versus Category 2 transfusions were compared by two-sample test of proportion.
RESULTS

Patient characteristics
There were 90 patients (82 at CHOA, eight at CNMC) who were enrolled between June 13, 2013, and May 27, 2015, and had 1134 transfusion episodes during the 12-month follow-up period. At study entry, 28 (31%) patients were receiving Category 2-matched transfusions (25 with RBC alloantibodies, three with only RBC autoantibodies). During the study period, two patients were switched from Category 1 to Category 2 matching: one patient with a past anti-e who was determined to have the RHCE genotype ce(733G)/ce(733G) and one patient who formed a new antibody of undetermined specificity (AUS) during the study. Thus 30 (33%) patients received Category 2-matched transfusions during the study. Baseline characteristics of the patients who received Category 1 versus Category 2 transfusions are compared in Table 1 showing slightly older age (mean, 10.7 years vs. 12.5 years; p 5 0.049).
At study entry, there were 41 known RBC alloantibodies in 26 patients. There were 20 (46.5%) antibodies within the Rh blood group (six anti-C, four anti-E, two anti-hr Table S1 (available as supporting information in the online version of this paper).
Donor RBC genotyping results
There were 2320 RBC units (1470 Category 1, 850 Category 2) transfused during the study period (Fig. 1 ). Of these, the donor HEA genotype was obtained in 2035 (1293 Category 1, 1742 Category 2): 1893 by HEA-LR assay and 142 from recorded donor HEA results. Of the 285 units without HEA genotypes, 89 were due to extremely low DNA concentration resulting in HEA-LR assay failure, and 196 were due to lack of unit segments for HEA-LR testing. The frequency of ICs per antigen is shown in Table S2 (available as supporting information in the online version of this paper).
HEA-LR assay concordance
The HEA-LR assay was performed on 1982 units, with assay failure in 89 (4.5%), yielding a success rate similar to previous analyses of HEA-LR. 24 The 2) at study completion. Two patients switched from Category 1 to Category 2 matched transfusions during the study. † Of the four patients in Category 2 with no alloantibodies at entry: three had autoantibodies, and one had no antibodies at entry but formed an AUS during the study. ‡ Of the 16 Category 2 patients with one alloantibody at entry: one patient was on Category 1 matching at entry but was switched to Category 2 when it was determined that a past anti-e was likely an alloantibody. with weak D expression. In two patients, RHCE SNPs could not be distinguished as cis (ce/ce(48C, 733G)) versus trans (ce(48C)/ce(733G)); thus they were categorized as conventional e1 expression, so as to not overestimate potential e antigen mismatches. Complete lists of patient RHCE and RHD genotypes and frequency of RhCE or RhD antibodies are in Tables S3 and S4 (available as supporting information in the online version of this paper). Among those with partial e genotypes, four of 29 (13.8%) had anti-e alloantibodies.
Antigen frequencies of SCA patients versus donor population
The RBC minor antigen frequencies of the 90 SCA patients were compared to the antigen frequencies found in the 2034 donor units, as shown in Fig. 2 There was a trend toward higher frequency of V mismatch (21.4% vs. 15.1%, p 5 0.022) and VS mismatch (20.0% vs. 13.8%, p 5 0.021); however, these were not significant findings when accounting for multiple comparisons.
RBC antibodies
During the study period, there was serologic detection of seven previously undetected RBC alloantibodies in five , and e variant determination) was not available, the frequency of these antigen exposures before alloantibody detection was not able to be determined. As shown in Fig. 4 , there were 74 Js a (-) patients, three of whom had anti-Js a before the study thus were receiving 
DISCUSSION
Red blood cell alloimmunization is a significant problem among SCA patients, despite minor antigen matching for C/c, E/e, and K as a recommended standard of care for all transfusions. 26 While many factors likely contribute to alloimmunization, [27] [28] [29] [30] exposure to a foreign RBC antigen is the required event to prompt antibody formation. However, it is not known how factors such as frequency or repetition of exposure contribute to the immunologic response. Likewise, the frequency of exposure to minor antigen mismatches during blood transfusion therapy in SCA has not been characterized previously. This study characterizes the specific RBC minor antigen mismatches that occur during CTT in SCA patients who are receiving minor antigen-matched transfusions. Karafin and coworkers 31 previously compared antigen frequencies of a cohort of SCA patients receiving C/c-, E/e-, and Kmatched transfusions to those of an African American-targeted donor program, showing that although there were no significant differences in antigen frequencies, there was ongoing development of alloimmunization, demonstrating that antigen mismatches remain problematic. Our study uniquely demonstrated the specific antigen matches per transfusion, allowing for comparisons in patients receiving limited versus extended antigen matching; additionally we were able to demonstrate the frequency of antigen exposure before new alloimmunization events in the case of Js a . While all transfusions were serologically matched for at least six antigens (D, C/c, E/e, K), this study examined 36 antigens, including determination of RHD and RHCE variants among patients that could result in potential Rh mismatches and alloimmunization. For both Category 1 and Category 2 transfusions, the median number of antigen mismatches per transfusion was low, a finding that is likely influenced by the imposed antigen matching protocols used for SCA. Antigen mismatches were more frequently observed for antigens in which the majority of patients were antigen negative (such as S, Doa, Fya, V, VS). Although antigen-matching protocols (C/c, E/e, K, with or without Fya and Jkb) allow for matching of many immunogenic RBC antigens, this conversely may increase patient exposure to other lower-frequency antigens that are more prevalent in African-origin populations than among Caucasian donors, such as V, VS, and Js a . It should be noted that the number of antigen mismatches may be slightly underrepresented due to a 1.6% rate of IC/LS calls per antigen on the HEA-LR results which were not considered donor/recipient mismatches in this study (see Table  S2 ). However, the implicated antigens with the highest IC/ LS rates (with the exception of Do a and Do b ) were unlikely to be mismatched based on either a high frequency of the IC/LS antigen in the patients (e.g., s antigen), intentional matching for the IC/LS antigen in the units (e.g., C antigen), or the almost universal presence of the Fyb GATA box mutation in SCD patients negating risk of alloimmunization (e.g., Fy b antigen).
In our study, there was a high frequency of RHCE homozygous or compound heterozygous variant genotypes lacking expression of conventional antigens. The main limitation of this study was the inability to fully evaluate for RHCE and RHD variant genotypes in the donor units, as the amount of DNA in leukoreduced unit segments is insufficient for PCR-based RH genotyping. Although RH variants were not thoroughly evaluated in the donor units, we presumed that there was a high frequency of Rh antigen mismatches among these patients, particularly with the transfusion of phenotypically e1 units to those with variant e expression. In our cohort, there also was a high frequency of alloimmunization to Rh antigens, similar to the frequency of Rh alloimmunization described by Chou and coworkers 4 in pediatric SCA patients who had similar transfusion matching, including patients with variant e genotypes who had recent development of antibodies with e-like specificity. As some of these Rh antibodies occur in patients with variant RH genotypes and others (such as anti-D) appear transiently among patients with apparent conventional RH genotypes, RH genotyping of both patients and donors is needed to distinguish RBC autoantibodies from Rh alloantibodies and to guide future transfusion antigen matching. Despite the fact that serologic antigen matching prevents exposure to some of the most immunogenic RBC antigens, there were seven alloimmunization events in five patients during the study period, and the majority of new alloantibodies were directed against low-frequency antigens that are not routinely tested by serologic phenotyping. Three of the new alloantibodies were directed against Js a , which occurs in less than 0.01% of Caucasians compared to 20% of individuals of African descent and was found to be mismatched in 13% of transfusions in the study period. Therefore, selection of C/c-, E/e-, and K-matched donors has shifted the pattern of antigen exposure and alloimmunization risk toward an antigen that is more prevalent among African-origin populations. By study completion, six SCA patients (6 whether the repetitive nature of the antigen exposure was a causative factor in developing a primary alloimmunization response or whether the immunologic response only became apparent once the alloantibody titers exceeded the threshold of detection by serologic antibody identification techniques; however, these findings do suggest that the frequency or "dosage" of antigen exposure may be a contributing factor to alloimmunization. Notable differences between chronically transfused SCA patients with prior RBC antibodies versus those without prior RBC antibodies were observed in this study. Although the rates of exposure to individual antigen mismatches, as well as the total number of mismatches per transfusion episode, were overall similar for these two groups of patients, the incidence of new RBC alloantibody detection was markedly higher among patients receiving Category 2-matched transfusions. This is in keeping with past observations that alloimmunized patients are a distinct group of immunologic "responders" who have a higher tendency of future alloantibody formation despite increased stringency of antigen matching. 27, [32] [33] [34] Of note, Category 2 patients were older and had a longer duration of CTT than Category 1 patients, which may confound the tendency toward alloimmunization. Further characterization of the immunologic differences between responder and nonresponder patients may help to prevent future alloimmunization. This study demonstrates that despite serologic RBC minor antigen matching for C/c, E/e, and K, as well as extended matching for Fy, Jk b , and any alloantibodies in patients with prior RBC antibodies, there remains a high frequency of individual antigen mismatches for several clinically significant antigens. Yet despite observing mismatch rates approaching nearly 50% of transfusions for some antigens, all of the alloimmunization events that occurred during the study frame were to low-frequency antigens. Therefore, although foreign antigen exposure is the requisite event for alloimmunization to occur, there are other factors that must contribute to this event, which may include donor and unit characteristics, patient's immunologic status, the immunogenicity of individual antigens, the frequency of antigen exposure, or the interaction of all of these factors. 27 This study suggests that alloimmunized patients may benefit from more stringent RBC antigen matching, especially to antigens that are more prevalent in donor populations that are ethnically similar to SCA patients, such as Js a . As further studies continue to explore the causes of RBC alloimmunization in SCA, examining the pattern of foreign antigen exposures before sensitization will be important in understanding the triggers for alloimmunization.
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